What is 10x Genomics, Inc.'s market cap?

10x Genomics, Inc. (TXG) has a market capitalization of $5.8B and trades on NASDAQ.

What is 10x Genomics, Inc.'s revenue and profitability?

10x Genomics, Inc. generated $638.8M in trailing twelve-month revenue with a net loss of $22.7M, representing a net margin of -3.5%. Gross margin stands at 69.6%, with free cash flow of $122.2M. These figures are based on the Q1 2026 filing.

Who are 10x Genomics, Inc.'s competitors?

10x Genomics, Inc.'s key competitors include Standard BioTools, Illumina, Inc., Quantum-Si Incorporated Class A Common Stock, and others. These companies compete in similar markets and product categories.

Who does 10x Genomics, Inc. partner with?

10x Genomics, Inc.'s notable partners include Harvard University, Stanford University.

What subsidiaries does 10x Genomics, Inc. have?

10x Genomics, Inc.'s subsidiaries include Scale Biosciences, Inc..

Where is 10x Genomics, Inc. headquartered?

10x Genomics, Inc. is headquartered in United States of America and employs approximately 1,259 people. It has been publicly traded since 2019.

10x Genomics, Inc.

TXG

10x Genomics is a life sciences technology company that develops integrated solutions for analyzing biological systems at high resolution and scale.

Market cap

$5.83B+240%

Revenue$638.8M+2.3%

Net income-$22.7M+85.6%

Free cash flow$122.2M+453%

EPS (diluted)-$0.17+87.0%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$150.8MBeat by $4.4M EPS-$0.10Beat by $0.19

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$146.7M

EPS estimate-$0.23

Financials

Q1 2026

Income statement

See full

Revenue$150.8M-2.6%

Gross profit$106.2M+0.7%

Operating income-$17.0M+56.7%

Net income-$13.5M+60.8%

EPS (diluted)-$0.10+64.3%

Balance sheet

See full

Cash & equivalents$490.3M+30.0%

Total debt$81.4M+1.6%

Total equity$814.3M+15.2%

Total assets$1.0B+12.4%

Cash flow

See full

Operating cash flow$26.1M-24.0%

CapEx$1.6M-15.6%

Free cash flow$24.5M-24.4%

Valuation & ratios

Valuation

See full

Market cap$5.83B+240%

Enterprise value$5.42B+263%

P/S9.1×+6.3×

Profitability

See full

Gross margin69.6%+1.2pp

Operating margin-6.1%-2.7pp

Net margin-3.5%-1.6pp

FCF margin19.1%—

Returns & leverage

See full

Return on equity-3%-1.4pp

Debt / equity0.1×0.0×

Current ratio5.9×+0.5×

Segments

By product

See full

Products and services revenue$149.9M+8.8%

Chromium$88.9M+5.7%

Services$8.8M+15.4%

Spatial$6.0M-32.2%

Single Cell$5.2M-11.7%

By geography

See full

Europe, Middle East and Africa$36.9M+15.5%

Asia-Pacific (excluding China)$18.1M+16.2%

Americas (excluding United States)$3.4M-9.2%

Competitors

By market cap

Agilent Technologies$38.9B+14.7%

Illumina$28.7B+64.8%

10x Genomics, Inc.$5.8B+223%

Standard BioTools Inc.$303.2M-40.9%

Nautilus Biotechnology, Inc.$211.0M+114%

Quanterix Corporation$172.9M-42.9%

Quantum-Si Incorporated$170.6M-52.7%

Bionano Genomics, Inc.$12.4M+12.7%

By revenue growth

Agilent Technologies+9.1%

Quanterix Corporation+6.9%

10x Genomics, Inc.+2.3%

Illumina+1.3%

By net margin

Agilent Technologies19.55%+2.0pp

Illumina19.42%+41.7pp

10x Genomics, Inc.-3.55%+21.6pp

Quanterix Corporation-71.86%-36.6pp

Profile

10x Genomics is a life sciences technology company that develops integrated solutions for analyzing biological systems at high resolution and scale. The company provides instruments, consumables, and software that enable researchers to interrogate biology at the single-cell and spatial levels, facilitating discoveries in oncology, immunology, and neuroscience. Its core value proposition lies in transforming complex biological data into actionable insights through multidisciplinary innovation in chemistry, hardware, and computational biology.

Competitive position

A leading provider of single-cell and spatial biology platforms with a significant installed base and a deep intellectual property portfolio.

GeographiesNorth America, Europe, Asia, Oceania, South America, Middle East, Africa

Customer segmentsAcademic research labs, Biopharmaceutical R&D, Government research institutions

Business modelRazor-and-blade, Hardware sales, Consumable recurring revenue

SuppliersContract manufacturers for instruments, Suppliers of critical reagents and enzymes, Oligonucleotide manufacturers, Academic IP licensors

CustomersPrincipal investigators, Core facility directors, Biopharmaceutical R&D departments, Clinical research organizations

CountryUnited States of America

Listed2019

Employees1.3K

CEOSerge Saxonov

SectorHealthcare

IndustryMedical - Healthcare Information Services

Website10xgenomics.com

FilingsSEC EDGAR

Ask your AI about 10x Genomics, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is 10x Genomics, Inc.'s market cap?: 10x Genomics, Inc. (TXG) has a market capitalization of $5.8B and trades on NASDAQ.
What is 10x Genomics, Inc.'s revenue and profitability?: 10x Genomics, Inc. generated $638.8M in trailing twelve-month revenue with a net loss of $22.7M, representing a net margin of -3.5%. Gross margin stands at 69.6%, with free cash flow of $122.2M. These figures are based on the Q1 2026 filing.
Who are 10x Genomics, Inc.'s competitors?: 10x Genomics, Inc.'s key competitors include Standard BioTools, Illumina, Inc., Quantum-Si Incorporated Class A Common Stock, and others. These companies compete in similar markets and product categories.
Who does 10x Genomics, Inc. partner with?: 10x Genomics, Inc.'s notable partners include Harvard University, Stanford University.
What subsidiaries does 10x Genomics, Inc. have?: 10x Genomics, Inc.'s subsidiaries include Scale Biosciences, Inc..
Where is 10x Genomics, Inc. headquartered?: 10x Genomics, Inc. is headquartered in United States of America and employs approximately 1,259 people. It has been publicly traded since 2019.